A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Nivolumab (Primary) ; PT 2385 (Primary)
- Indications Renal cancer; Renal cell carcinoma
- Focus Adverse reactions; First in man
- Sponsors Peloton Therapeutics
- 23 Aug 2017 Planned number of patients changed from 151 to 107.
- 23 Aug 2017 Planned End Date changed from 1 Sep 2018 to 1 Dec 2018.
- 23 Aug 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Aug 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History